Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Pill that mimics Viagra can slow Alzheimer’s progression, study suggests

Experts call trial results of medication that slowed cognitive decline by almost a third ‘very promising’ A pill that mimics Viagra by relaxing blood vessels and increasing blood flow to the brain can slow cognitive decline in people with Alzheimer’s disease by almost a third, a global study suggests. Alzheimer’s is the most common form of dementia, a condition that is forecast to affect 153…

Pill that mimics Viagra can slow Alzheimer’s progression, study suggests

A pill resembling Viagra, which enlarges blood vessels and boosts cerebral blood flow, has exhibited the potential to decelerate cognitive decline in Alzheimer’s patients by approximately one-third, according to the outcomes of a global phase III trial, according to experts. Alzheimer’s disease, the most prevalent form of dementia, is anticipated to afflict 153 million individuals by 2050, and presently, there remains no cure.

The trial, encompassing 13 countries, including the UK, unveiled that the tablet AR1001 diminished decline by 31% in patients with early Alzheimer’s disease who were not receiving any supplementary treatment.

Medical professionals not associated with the study conveyed both caution and enthusiasm regarding the results, deeming them "exciting" and "very promising," as they may herald the emergence of an innovative treatment for Alzheimer’s. Presented at the Clinical Trials on Alzheimer’s Disease conference in Boston, the study demonstrated that AR1001 was a phosphodiesterase-5 inhibitor, akin to Viagra, which is employed to address erectile dysfunction.

The South Korean company AriBio, which manufactures AR1001, reported that the drug decelerated decline in 604 individuals who were not concurrently administering any other drugs for Alzheimer’s.

Prof Tara Spires-Jones, a neurodegeneration expert at the University of Edinburgh, described the results as "very promising," explaining that the drug functions by enhancing blood circulation and potentially directly stimulating brain cell pathways that foster learning and memory. Dr Sheona Scales, director of research at Alzheimer’s Research UK, termed the findings "very encouraging," marking "an important milestone in the search for new Alzheimer’s treatments."

She emphasized that AR1001 distinguished itself by being an oral medication that employed a "different approach" to existing treatments, acting on a specific enzyme and influencing several other processes involved in brain function.

Dr Richard Oakley, associate director of research and innovation at Alzheimer’s Society, expressed optimism, stating that AR1001 held the potential to introduce a "totally new treatment" for early Alzheimer’s disease by targeting its causes rather than merely its symptoms. The drug operates by relaxing blood vessels to augment blood flow to the brain, and unlike other disease-modifying treatments that have demonstrated efficacy in late-stage trials, it is administered as a once-daily tablet, potentially simplifying treatment.

AR1001's effectiveness was most pronounced in patients who did not concurrently take other drugs for Alzheimer’s symptoms; however, further investigation was required to ascertain its efficacy across the broader trial cohort. All experts called for additional trials to scrutinize AR1001 thoroughly before it could be prescribed for Alzheimer’s treatment.

Written by urgent.news from Guardian Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at theguardian.com →

More in Health & Medicine

More from Wednesday 18 November →